Company Overview of Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. engineers antibody-drug conjugates that maximize the potential of new and established therapeutic classes. The company develops a portfolio of antibody-drug conjugates to improve patient outcomes in multiple oncology indications. Its clinical-stage product candidates include XMT-1001, a “tecan” conjugate for patients with lung cancers; and XMT-1107, an anti-angiogenic conjugate for patients with refractory, advanced solid tumors. The company’s conjugation system provides benefits for the development of drugs across therapeutic modalities, including antibody-drug conjugates, antibody fragments, small molecules, biologics, and synergistic drug combinations. Mersana T...
840 Memorial Drive
Cambridge, MA 02139
Founded in 2001
Key Executives for Mersana Therapeutics, Inc.
Chief Executive Officer, President and Director
Vice President of Finance
Head of Clinical Development & Regulatory Affairs
Compensation as of Fiscal Year 2015.
Mersana Therapeutics, Inc. Key Developments
Mersana Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 03:40 PM
Aug 4 15
Mersana Therapeutics, Inc. Presents at Wedbush PacGrow Healthcare Conference 2015, Aug-12-2015 03:40 PM. Venue: Le Parker Meridian, 119 West 56th Street, New York, NY 10019, United States.
Mersana Therapeutics, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015
May 17 15
Mersana Therapeutics, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Eva M. Jack, Chief Business Officer.
Mersana Therapeutics, Inc. Announces Preclinical Data for its Lead Product Candidate, XMT-1522
Apr 18 15
Mersana Therapeutics, Inc. announced that preclinical data for its lead product candidate, XMT-1522, demonstrated significant anti-cancer activity in low HER2-expressing tumor models refractory to currently available therapies, as well as HER2-amplified tumor models in combination with trastuzumab-based therapies. These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 21 in Philadelphia, PA. XMT-1522 is a novel HER2-targeting therapy based on Mersana's FleximerÂ® immunoconjugate technology that carries an average of 15 proprietary auristatin payload molecules. The conjugate, optimized for payload delivery, utilizes a novel HER2-targeted antibody, which binds to a different epitope than existing anti-HER2 antibodies. Single doses of 1 mg/kg or 0.67 mg/kg of XMT-1522 showed complete regression in low HER2-expressing breast and gastric cancer models, where ado-trastuzumab emtansine was inactive at doses of 10 mg/kg and above. In HER2-driven tumor models, XMT-1522 showed synergistic efficacy in combination with widely used anti-HER2 therapies trastuzumab and pertuzumab. XMT-1522 demonstrated an excellent pharmacokinetic profile and was well tolerated in non-human primates at therapeutic doses.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 20, 2015